title: Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors.
abstract: BACKGROUND
  Temozolomide has shown activity and limited toxicity in patients with primary brain tumors at doses of 150-200 mg/m(2)/day on days 1-5 every 4 weeks. In this study, a new alternative dose-dense regimen of temozolomide was explored in patients with recurrent brain tumors.
  
  
  METHODS
  In this study, we evaluated the safety, dose-limiting toxicity, maximum tolerated dose, recommended dose and activity of temozolomide given on days 1-3 and 14-16 every 28 days (one cycle). The starting daily dose was 200 mg/m(2) in a group of at least six patients, with subsequent increments of 50 mg/m(2) in groups of at least 12 patients until unacceptable toxicity was reached. Oral ondansetron (8 mg) was given 1 h prior to temozolomide administration. McDonald's criteria were used to evaluate antitumor activity.
  
  
  RESULTS
  Seventy patients with brain tumors entered this study. The median number of prior chemotherapy treatments was two (range 1-3). Patients were assigned to one of four groups to receive temozolomide at daily doses of 200 (seven patients), 250 (13 patients), 300 (38 patients) and 350 mg/m(2)/day (12 patients). The absence of dose-limiting toxicity at cycle 1 led us to establish dose recommendations based on toxicity after repeated cycles. A total of 23, 72, 192 and 83 cycles were given at daily doses of 200, 250, 300 and 350 mg/m(2), respectively. Grade 3-4 thrombocytopenia was observed in 0/7, 1/13, 5/38 and 4/12 patients treated at doses of 200, 250, 300 and 350 mg/m(2)/day, respectively. Grade 3-4 neutropenia was observed in 1/7, 0/13, 3/38 and 4/12 patients treated with 200, 250, 300 and 350 mg/m(2)/day temozolomide, respectively. At a dose of 350 mg/m(2), sustained grade 2-3 thrombocytopenia did not allow treatment to be resumed at day 14 in >40% of patients, and this dose was considered to be the maximum tolerated dose. Thus, a dose of 300 mg/m(2)/day that was associated with <20% treatment delay due to sustained hematological toxicity was considered as the recommended dose. Objective responses were reported in 13 patients.
  
  
  CONCLUSIONS
  Temozolomide can be given safely using a dose-dense regimen of 300 mg/m(2)/day for 3 consecutive days every 2 weeks in patients with recurrent brain tumors.
authors.affiliation: Department of Medicine, Institute Gustave-Roussy, Villejuif, France.
authors.forename: K
authors.initials: K
authors.lastname: Vera
authors.forename: L
authors.initials: L
authors.lastname: Djafari
authors.forename: S
authors.initials: S
authors.lastname: Faivre
authors.forename: J-S
authors.initials: JS
authors.lastname: Guillamo
authors.forename: K
authors.initials: K
authors.lastname: Djazouli
authors.forename: M
authors.initials: M
authors.lastname: Osorio
authors.forename: F
authors.initials: F
authors.lastname: Parker
authors.forename: C
authors.initials: C
authors.lastname: Cioloca
authors.forename: B
authors.initials: B
authors.lastname: Abdulkarim
authors.forename: J-P
authors.initials: JP
authors.lastname: Armand
authors.forename: E
authors.initials: E
authors.lastname: Raymond
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D017294:Ondansetron / Q000008:administration & dosage / Q000009:adverse effects; D000077204:Temozolomide
chemical_list: D017294:Ondansetron; D003606:Dacarbazine; D000077204:Temozolomide